Lundgren H, Bengtsson C, Lapidus L, Bengtsson L
Health Centre of Floda, Gothenburg University, Sweden.
J Intern Med. 1990 Dec;228(6):597-602. doi: 10.1111/j.1365-2796.1990.tb00285.x.
Felodipine, a new antihypertensive calcium antagonist, was compared with metoprolol, a beta-blocker, and hydrochlorothiazide, a diuretic, with respect to glucose tolerance in a randomized double-blind cross-over study consisting of 11 patients, of age range 50-70 years, who had developed diabetes during antihypertensive treatment. Each treatment period lasted for 10 weeks. The blood pressure was similar irrespective of treatment. Serum glucose levels during the oral glucose tolerance test were significantly lower when the patients were treated with felodipine than when they were taking hydrochlorothiazide. Serum insulin levels appeared to decrease at an earlier stage of the test when the patients were treated with felodipine, the calcium antagonist, than with the other two antihypertensive substances, which suggests that glucose tolerance is impaired to a lesser extent during treatment with the calcium antagonist. Glucose tolerance was never completely normalized with any of the drugs tested.
在一项随机双盲交叉研究中，将新型抗高血压钙拮抗剂非洛地平与β受体阻滞剂美托洛尔及利尿剂氢氯噻嗪进行了比较，该研究纳入了11名年龄在50至70岁之间、在抗高血压治疗期间患糖尿病的患者。每个治疗期持续10周。无论采用何种治疗，血压均相似。口服葡萄糖耐量试验期间，患者服用非洛地平时的血清葡萄糖水平显著低于服用氢氯噻嗪时。与其他两种抗高血压药物相比，患者服用钙拮抗剂非洛地平时，血清胰岛素水平在试验早期似乎下降，这表明钙拮抗剂治疗期间葡萄糖耐量受损程度较小。所测试的任何药物均未使葡萄糖耐量完全恢复正常。
